Guided Therapeutics, Inc. (GTHP)
| Market Cap | 5.01M |
| Revenue (ttm) | 82,000 |
| Net Income (ttm) | -3.02M |
| Shares Out | 55.69M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 0.0900 |
| Previous Close | 0.1000 |
| Day's Range | n/a |
| 52-Week Range | 0.0620 - 0.3000 |
| Beta | 0.62 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 29, 2023 |
About GTHP
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 199... [Read more]
Financial Performance
In 2023, GTHP's revenue was $98,000, an increase of 653.85% compared to the previous year's $13,000. Losses were -$3.49 million, -29.83% less than in 2022.
Financial StatementsNews
Leading Cervical Cancer Doctors Support Approval of LuViva in China Based on Preliminary Review of Clinical Trial Results
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that a group of prominent cervical cancer doctors are ...
Guided Therapeutics Announces Completion of Clinical Study for Chinese Regulatory Approval
PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)-- #HPV--Guided Therapeutics, Inc. (OTCQB: GTHP) announced today the completion of the clinical trial for marketing and sales approval of the Company's LuViva Ad...